Pathophysiological basis and diagnosis of the cardiovascular system damage caused by coronavirus infection
https://doi.org/10.18087/cardio.2022.3.n1468
Abstract
This review focuses on the pathogenesis, most common clinical manifestations, and methods for diagnosis of damages to the cardiovascular system in coronavirus infection. The search for studies to be reviewed included publications of Elsevier, PubMed, and Web of Science resources by the key words “COVID-19”, “myocarditis”, “coronavirus”, and “myocardial injury”. The clinical presentation of coronavirus infection can include acute heart failure, myocardial injury, arrhythmias, pericarditis, venous thromboembolism, and microcirculatory dysfunction. Since symptoms of this pathology are non-specific, it is important to pay attention to monitoring of clinical laboratory and instrumental indexes for early differential diagnosis of cardiovascular disease. In all cases of parameter deviation from the normal range, cardiovascular complications of COVID-19 should be suspected. Measures should be taken for specifying the occurrence and severity of cardiac and/or vascular injury, and approaches should be developed for comprehensive treatment or prevention of these conditions.
About the Authors
E. K. SerezhinaRussian Federation
therapist, PhD
Saint Petersburg
A. G. Obrezan
Russian Federation
professor, chef doctor
Saint Petersburg
References
1.
2. World Health Organisation. WHO Director-General’s remarks at the media briefing on 2019-nCoV on 11 February 2020. [Internet] Available at: https://www.who.int/director-general/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020
3. Lang JP, Wang X, Moura FA, Siddiqi HK, Morrow DA, Bohula EA. A current review of COVID-19 for the cardiovascular specialist. American Heart Journal. 2020; 226:29–44. DOI: 10.1016/j.ahj.2020.04.025
4. The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team null. The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) - China, 2020. China CDC weekly. 2020;2(8):113–22. PMID: 34594836
5. Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clinical Research in Cardiology. 2020;109(5):531–8. DOI: 10.1007/s00392-020-01626-9
6. Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F et al. Association of Cardiac Injury with Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiology. 2020;5(7):802–10. DOI: 10.1001/jamacardio.2020.0950
7. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet. 2020;395(10229):1054–62. DOI: 10.1016/S0140-6736(20)30566-3
8. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020;368:m1091. DOI: 10.1136/bmj.m1091 8. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–9. DOI: 10.1001/jama.2020.1585
9. Wang T, Chen R, Liu C, Liang W, Guan W, Tang R et al. Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19. The Lancet Haematology. 2020;7(5):e362–3. DOI: 10.1016/S2352-3026(20)30109-5
10. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020;395(10223):497–506. DOI: 10.1016/S0140-6736(20)30183-5
11. Guo T, Fan Y, Chen M, Wu X, Zhang L, He T et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiology. 2020;5(7):811–8. DOI: 10.1001/jamacardio.2020.1017
12. Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thrombosis Research. 2020;191:145–7. DOI: 10.1016/j.thromres.2020.04.013
13. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet. 2020;395(10223):507–13. DOI: 10.1016/S0140-6736(20)30211-7
14. Wang Z, Wang D, Dai Y, Zhu S, Zeng H. Urogenital System Damaging Manifestations of 3 Human Infected Coronaviruses. Journal of Urology. 2021;205(3):671–7. DOI: 10.1097/JU.0000000000001400
15. Liu K, Fang Y-Y, Deng Y, Liu W, Wang M-F, Ma J-P et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chinese Medical Journal. 2020;133(9):1025–31. DOI: 10.1097/CM9.0000000000000744
16. Chen L, Li X, Chen M, Feng Y, Xiong C. The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. Cardiovascular Research. 2020;116(6):1097–100. DOI: 10.1093/cvr/cvaa078
17. Zhang MQ, Wang XH, Chen YL, Zhao KL, Cai YQ, An CL et al. Clinical features of 2019 novel coronavirus pneumonia in the early stage from a fever clinic in Beijing. Zhonghua Jie He He Hu Xi Za Zhi. 2020;43(3):215–8. DOI: 10.3760/cma.j.issn.1001-0939.2020.03.015
18. Doyen D, Moceri P, Ducreux D, Dellamonica J. Myocarditis in a patient with COVID-19: a cause of raised troponin and ECG changes. The Lancet. 2020;395(10235):1516. DOI: 10.1016/S0140-6736(20)30912-0
19. Hu H, Ma F, Wei X, Fang Y. Coronavirus fulminant myocarditis treated with glucocorticoid and human immunoglobulin. European Heart Journal. 2020;42(2):206. DOI: 10.1093/eurheartj/ehaa190
20. Inciardi RM, Lupi L, Zaccone G, Italia L, Raffo M, Tomasoni D et al. Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19). JAMA Cardiology. 2020;5(7):819–24. DOI: 10.1001/jamacardio.2020.1096
21. Irabien-Ortiz Á, Carreras-Mora J, Sionis A, Pàmies J, Montiel J, Tauron M. Fulminant myocarditis due to COVID-19. Revista Española de Cardiología (English Edition). 2020;73(6):503–4. DOI: 10.1016/j.rec.2020.04.005
22. Kim I-C, Kim JY, Kim HA, Han S. COVID-19-related myocarditis in a 21-year-old female patient. European Heart Journal. 2020;41(19):1859–1859. DOI: 10.1093/eurheartj/ehaa288
23. Paul J-F, Charles P, Richaud C, Caussin C, Diakov C. Myocarditis revealing COVID-19 infection in a young patient. European Heart Journal – Cardiovascular Imaging. 2020;21(7):776. DOI: 10.1093/ehjci/jeaa107
24. Sala S, Peretto G, Gramegna M, Palmisano A, Villatore A, Vignale D et al. Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infection. European Heart Journal. 2020;41(19):1861–2. DOI: 10.1093/eurheartj/ehaa286
25. Tavazzi G, Pellegrini C, Maurelli M, Belliato M, Sciutti F, Bottazzi A et al. Myocardial localization of coronavirus in COVID‐19 cardiogenic shock. European Journal of Heart Failure. 2020;22(5):911–5. DOI: 10.1002/ejhf.1828
26. Zeng J-H, Liu Y-X, Yuan J, Wang F-X, Wu W-B, Li J-X et al. First case of COVID-19 complicated with fulminant myocarditis: a case report and insights. Infection. 2020;48(5):773–7. DOI: 10.1007/s15010-020-01424-5
27. Ministry of Health of Russian Federation. Temporary methodical recommendations. Prevention, diagnosis and treatment of new coronavirus infection (COVID-2019). Version 14 (27.12.2021). Av. at: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/059/041/original/%D0%92%D0%9C%D0%A0_COVID-19_V14_27-12-2021.pdf. 2021.
28. Dweck MR, Bularga A, Hahn RT, Bing R, Lee KK, Chapman AR et al. Global evaluation of echocardiography in patients with COVID-19. European Heart Journal Cardiovascular Imaging. 2020;21(9):949–58. DOI: 10.1093/ehjci/jeaa178
29. Giustino G, Croft LB, Stefanini GG, Bragato R, Silbiger JJ, Vicenzi M et al. Characterization of Myocardial Injury in Patients with COVID-19. Journal of the American College of Cardiology. 2020;76(18):2043–55. DOI: 10.1016/j.jacc.2020.08.069
30. Tersalvi G, Vicenzi M, Calabretta D, Biasco L, Pedrazzini G, Winterton D. Elevated Troponin in Patients with Coronavirus Disease 2019: Possible Mechanisms. Journal of Cardiac Failure. 2020;26(6):470–5. DOI: 10.1016/j.cardfail.2020.04.009
31. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. Journal of Clinical Investigation. 2020;130(5):2620–9. DOI: 10.1172/JCI137244
32. Monpara JD, Sodha SJ, Gupta PK. COVID-19 associated complications and potential therapeutic targets. European Journal of Pharmacology. 2020;886: 173548. DOI: 10.1016/j.ejphar.2020.173548
33. Kichloo A, Dettloff K, Aljadah M, Albosta M, Jamal S, Singh J et al. COVID-19 and Hypercoagulability: A Review. Clinical and Applied Thrombosis/Hemostasis. 2020;26: 107602962096285. DOI: 10.1177/1076029620962853
34. Giustino G, Pinney SP, Lala A, Reddy VY, Johnston-Cox HA, Mechanick JI et al. Coronavirus and Cardiovascular Disease, Myocardial Injury, and Arrhythmia. Journal of the American College of Cardiology. 2020;76(17):2011–23. DOI: 10.1016/j.jacc.2020.08.059
35. Serezhina E.K., Obrezan A.G. Cardiovascular Pathology in Patients With COVID-19. Kardiologiia. 2020;60(8):23–6. DOI: 10.18087/cardio.2020.8.n1215
36. Boukhris M, Hillani A, Moroni F, Annabi MS, Addad F, Ribeiro MH et al. Cardiovascular Implications of the COVID-19 Pandemic: A Global Perspective. Canadian Journal of Cardiology. 2020;36(7):1068–80. DOI: 10.1016/j.cjca.2020.05.018
37. Shlyakho E.V., Konradi A.O., Arutyunov G.P., Arutyunov A.G., Bautin A.E., Boytsov S.A. et al. Guidelines for the diagnosis and treatment of circulatory diseases in the context of the COVID-19 pandemic. Russian Journal of Cardiology. 2020;25(3):129–48. DOI: 10.15829/1560-4071-2020-3-3801
Review
For citations:
Serezhina E.K., Obrezan A.G. Pathophysiological basis and diagnosis of the cardiovascular system damage caused by coronavirus infection. Kardiologiia. 2022;62(3):82-88. (In Russ.) https://doi.org/10.18087/cardio.2022.3.n1468